1. Canada Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
Diagnocure, Inc.

Diagnocure, Inc.

DGCRF
Diagnocure, Inc.US flagOther OTC
0.00
USD
- -
- -
21,520.00Market Cap
2003 Y
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
TTM
Revenue per Share
0.03
0.19
0.15
0.12
0.06
0.05
0.04
0.03
0.03
0.06
0.02
0.01
0.01
0.16
Basic EPS, GAAP
-0.11
-0.01
-0.09
-0.21
-0.24
-0.33
-0.3
-0.21
-0.03
-0.09
-0.08
-0.05
-0.08
0.06
Free Cash Flow per Basic Share
-0.1
- -
-0.13
-0.13
-0.2
-0.31
-0.28
-0.18
-0.06
-0.07
-0.04
-0.04
-0.03
-0.03
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-1.1
-1.09
-1.09
-1.29
-1.44
0.53
-1.92
-2.12
-2.14
-0.09
-0.17
-0.22
-0.3
-2.32
Tangible Book Value per Share
0.16
0.86
0.73
0.56
0.82
0.45
0.19
0.04
0.06
0.01
-0.04
-0.08
-0.11
0.01
Basic Weighted Avg Shares
29
31
34
34
38
42
43
43
43
43
43
43
43
43
Sales/Revenue/Turnover
1
6
5
4
2
2
2
1
1
2
1
1
1
7
Operating Margin (%)
-413.49
-11.64
-73.69
-170.91
-394.85
-693.92
-794.68
-422.46
-303.79
-151.97
-541.02
-376.88
-704.84
40.87
Depreciation Expense
- -
- -
- -
- -
1
2
2
1
1
1
1
- -
- -
- -
Net Income, GAAP
-3
- -
-3
-7
-9
-14
-13
-9
-1
-4
-4
-2
-4
3
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-416.39
-7.13
-60.38
-166.99
-402.91
-693.12
-796.27
-744.65
-101.83
-148.84
-531.41
-367.38
-698.56
41
Working Capital
4
13
18
12
24
10
13
7
7
5
4
2
1
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
5
27
25
20
40
30
23
15
14
10
7
5
1
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
126.55
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-5.24
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jan'16
Apr'16
Jul'16
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
6
- -
- -
Shares Outstanding
43
43
43
Market Capitalization
6
1
- -

Working Capital

FRC

•

in mil. unless spec.
Jan'16
Apr'16
Jul'16
Total Current Assets
1
1
1
Cash, Cash Equivalents & STI
1
1
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-16.54%
-32.67%
-70.96%
Free Cash Flow
-1.6%
-23.03%
-38.07%
Net Income, GAAP
31.06%
27.28%
77.16%
Sales/Revenue/Turnover
-11.37%
1.33%
-6.83%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
- -
- -
- -
- -
1
2015
- -
- -
- -
- -
1
2016
- -
6
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
-0.01
-0.01
-0.01
- -
-0.05
2015
-0.01
-0.01
-0.01
- -
-0.08
2016
-0.01
0.13
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -

Company Description

MCPAPIChat
CEO
Yves Fradet F.R.C.S.,
Full Time Employees
3
Sector
Healthcare
Industry
Medical - Specialties
Address
4535 Wilfrid-Hamel Boulevard Quebec QC Canada G1P 2J7
IPO Date
Sep 8, 2009
Website
diagnocure.com
Similar Companies
Strategic Global Investments, Inc. (STBV)
WON TECH Co.,Ltd. (336570.KQ)
Sonomax Technologies Inc (SXHHF)
Curexo Inc. (060280.KQ)
Basma Adeem Medical Co. (9626.SR)
Jenscare Scientific Co., Ltd. (9877.HK)
Business
DiagnoCure Inc. DiagnoCure Inc. (TSX: CUR; OTCQX: DGCRF), founded in 1998 and headquartered in Quebec City, Quebec, Canada, operates as a life sciences company focused on the development and commercialization of molecular and genomic diagnostic tests for cancer detection and management; its core products include the PROGENSA PCA3 assay for prostate cancer diagnosis, which detects prostate cancer-associated 3 gene expression in urine to aid decisions on repeat biopsies; the Previstage GCC colorectal cancer staging test utilizing guanylyl cyclase C markers to assess lymph node involvement; and related laboratory services supporting clinician decision-making in genitourinary and breast cancers. The company targets healthcare providers and patients primarily in North America and Europe, with operations centered in Canada and historical U.S. commercialization efforts through partnerships. In recent developments, DiagnoCure sold its PCA3 assets to Hologic Inc. Hologic, Inc. via Gen-Probe, enabling a special distribution to shareholders and a strategic pivot toward preserving liquidity through operational restructuring; it previously acquired high-value diagnostic tests for breast and colon cancer from Catalyst Oncology and established U.S. commercial operations to expand market reach.